الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 97 |  |  |
| | | from | 97 | | |
Abstract
Summary
Egypt has possibly the one of highest HCV prevalence in the world, 10%-20% of the general population is infected and HCV is the leading cause of chronic liver disease and HCC in the country.
The US FDA has (6 December, 2013) approved DAAs for the treatment chronic HCV infection, because it has shown a substantial improvement over the other available therapies.
The most interesting feature of this approval lies in the fact that this drug can be administered without the need of interferon therapy.
Impairment of tear function and squamous metaplastic changes in the ocular surface are reported as the only ophthalmologic complications in patients with chronic hepatitis C treated with sofosbuvir combined with other antivirals.
The study was carried on consecutive patients with chronic hepatitis C referred from hepatology department of Natinal Liver Institute to outpatient clinic of ophthalmology in Menoufia University hospital, during the period of study .This study was performed on 100 cases .The patients were treated with (sofosbuvir+ daclatasvir+- ribavirin) for 3 monthes. They were submitted to clinical examination including fundus examination before therapy with periodic examination after therapy and 3months later. The incidence of retinopathy with (sofosbuvir and ribavirin) was reported to be 0%.
The incidence of retinopathy with (ribavirin and pegIFNα) was reported to be 18-86%.The retinopathy is generally mild, most frequently asymptomatic and usually resolves completely during therapy or quickly after therapy.